A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples

Dean Follmann, Lauren Dang, Eric Chun‐Pu Chu, Jonathan Fintzi, Holly Janes, Peter B. Gilbert, Leah Andrews, Leonid Serebryannyy, Robin Carroll, Bob C. Lin, Richard A. Koup, Jon Toma, L Weiping Deng, Frances Priddy, Avika Dixit, Haiyu Zhou, Lindsey R. Baden, Hana M. El SahlyThe Journal of Infectious Diseases 2025 · DOI

Abstract

Traditional vaccine clinical trials sample blood from all participants. In contrast, the test-negative immune correlates (TNIC) design only samples blood from participants who develop symptoms. We compared traditional to test-negative immune correlates methods in the mRNA-1273 severe acute respiratory syndrome coronavirus 2 vaccine efficacy clinical trial. Using a neutralizing antibody assay, hazard ratios were 0.48 (95% confidence interval [CI], .29-.73) and 0.55 (95% CI, .28-1.06) for traditional and test-negative methods, respectively. Analogous ratios for binding antibody assay were 0.69 (95% CI, .52-.94) and 0.78 (95% CI, .50-1.20). The results support use of the logistically simpler TNIC design.
BibTeX
@article{follmann2025test,
  author = {Dean Follmann and Lauren Dang and Eric Chun‐Pu Chu and Jonathan Fintzi and Holly Janes and Peter B. Gilbert and Leah Andrews and Leonid Serebryannyy and Robin Carroll and Bob C. Lin and Richard A. Koup and Jon Toma and L Weiping Deng and Frances Priddy and Avika Dixit and Haiyu Zhou and Lindsey R. Baden and Hana M. El Sahly},
  title = {{A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples}},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf572},
}

Loading related content...

Figure